Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocrelizumab - Biogen/Genentech

Next Previous
Drug Profile

Ocrelizumab - Biogen/Genentech

Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; OCRE; Ocrevus; Ocrevus SC; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913

Latest Information Update: 09 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Genentech
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 29 Feb 2024 Updated pharmacokinetics and safety data from the phase III OCARINA II trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2024)
  • 29 Feb 2024 Updated safety data from the phase Ib OCARINA I trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2024)
  • 31 Dec 2023 Preregistration for Multiple sclerosis in United Kingdom (SC) before December 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top